{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:48:36Z","timestamp":1789620516413,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1007\/s11912-006-0046-0","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T20:05:37Z","timestamp":1180123537000},"page":"114-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Interleukins 18 and 21: Biology, mechanisms of action toxicity, and clinical activity"],"prefix":"10.1007","volume":"8","author":[{"given":"Theodore F.","family":"Logan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"46_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000386035","volume":"13","author":"FM Burnet","year":"1970","unstructured":"Burnet FM: The concept of immunological surveillance. Prog Exp Tumor Res 1970, 13:1\u201327.","journal-title":"Prog Exp Tumor Res"},{"key":"46_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0167-5699(97)80020-5","volume":"18","author":"T Boon","year":"1997","unstructured":"Boon T, Coulie PG, Van den Eynde B: Tumor antigens recognized by T cells. Immunol Today 1997, 18:267\u2013268.","journal-title":"Immunol Today"},{"key":"46_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1084\/jem.187.8.1163","volume":"187","author":"LJ Old","year":"1998","unstructured":"Old LJ, Chen YT: New paths in human cancer serology. J Exp Med 1998, 187:1163\u20131167.","journal-title":"J Exp Med"},{"key":"46_CR4","first-page":"601","volume-title":"Principles and Practice of the Biologic Therapy of Cancer","author":"FM Marincola","year":"2000","unstructured":"Marincola FM: Cancer vaccines: basic principles. Mechanisms of immune escape and immune tolerance. In Principles and Practice of the Biologic Therapy of Cancer, edn 3. Edited by Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins; 2000:601\u2013617.","edition":"edn 3"},{"key":"46_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0092-8674(94)90336-0","volume":"76","author":"RN Germain","year":"1994","unstructured":"Germain RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994, 76 28Januay:287\u2013299.","journal-title":"Cell"},{"key":"46_CR6","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","volume":"12","author":"P Matzinger","year":"1994","unstructured":"Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 1994, 12:991\u20131045.","journal-title":"Annu Rev Immunol"},{"key":"46_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.0105-2896.2004.00199.x","volume":"202","author":"MJ Smyth","year":"2004","unstructured":"Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y: Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004, 202:275\u2013293. An excellent and up-to-date review of cytokines and their role in cancer immunology\/immunotherapy.","journal-title":"Immunol Rev"},{"key":"46_CR8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/iai.38.2.440-443.1982","volume":"38","author":"H Okamura","year":"1982","unstructured":"Okamura H, Kawaguchi K, Shoji K, Kawade Y: High-level induction of gamma interferon with various mitogens in mice pretreated with Propionibacterium acnes. Infect Immun 1982, 38:440\u2013443.","journal-title":"Infect Immun"},{"key":"46_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/378088a0","volume":"378","author":"H Okamura","year":"1995","unstructured":"Okamura H, Tsutsi H, Komatsu T, et al.: Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995, 378:88\u201391.","journal-title":"Nature"},{"key":"46_CR10","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.4049\/jimmunol.156.11.4274","volume":"156","author":"S Ushio","year":"1996","unstructured":"Ushio S, Namba M, Okura T, et al.: Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996, 156:4274\u20134279.","journal-title":"J Immunol"},{"key":"46_CR11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/379591a0","volume":"379","author":"JF Bazan","year":"1996","unstructured":"Bazan JF, Timans JC, Kastelein RA: A newly defined interleukin-1? Nature 1996, 379:591.","journal-title":"Nature"},{"key":"46_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1126\/science.275.5297.206","volume":"275","author":"Y Gu","year":"1997","unstructured":"Gu Y, Kuida K, Tsutsui H, et al.: Activation of interferongamma inducing factor mediated by interleukin-1beta converting enzyme. Science 1997, 275:206\u2013209.","journal-title":"Science"},{"key":"46_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1189\/jlb.0602313","volume":"73","author":"JA Gracie","year":"2003","unstructured":"Gracie JA, Robertson SE, McInnes IB: Interleukin-18. J Leukoc Biol 2003, 73:213\u2013224. A good recent review of the overall biology of IL-18.","journal-title":"J Leukoc Biol"},{"key":"46_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1086\/315656","volume":"182","author":"R Vankayalapati","year":"2000","unstructured":"Vankayalapati R, Wizel B, Weis SE, et al.: Production of interleukin-18 in human tuberculosis. J Infect Dis 2000, 182:234\u2013239.","journal-title":"J Infect Dis"},{"key":"46_CR15","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.4049\/jimmunol.162.12.7322","volume":"162","author":"J Pirhonen","year":"1999","unstructured":"Pirhonen J, Sareneva T, Kurimoto M, et al.: Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway. J Immunol 1999, 162:7322\u20137329.","journal-title":"J Immunol"},{"key":"46_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1006\/clin.1997.4475","volume":"86","author":"K Kohno","year":"1998","unstructured":"Kohno K, Kurimoto M: Interleukin 18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. Clin Immunol Immunopathol 1998, 86:11\u201315. This is an excellent review of the early development of IL-18.","journal-title":"Clin Immunol Immunopathol"},{"key":"46_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/01.moh.0000141926.95319.42","volume":"11","author":"P Reddy","year":"2004","unstructured":"Reddy P: Interleukin-18: recent advances. Curr Opin Hematol 2004, 11:405\u2013410.","journal-title":"Curr Opin Hematol"},{"key":"46_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1084\/jem.194.3.343","volume":"194","author":"M Neighbors","year":"2001","unstructured":"Neighbors M, Xu X, Barrat FJ, et al.: A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on interferon gamma production. J Exp Med 2001, 194:343\u2013354.","journal-title":"J Exp Med"},{"key":"46_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1084\/jem.194.3.355","volume":"194","author":"H Helmby","year":"2001","unstructured":"Helmby H, Takeda K, Akira S, Grencis RK: Interleukin (IL)-18 promotes the development of chronic gastrointestinal helminth infection by downregulating IL-13. J Exp Med 2001, 194:355\u2013364.","journal-title":"J Exp Med"},{"key":"46_CR20","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1182\/blood-2002-07-2322","volume":"103","author":"A Kaser","year":"2004","unstructured":"Kaser A, Kaser S, Kaneider NC, et al.: Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood 2004, 103:648\u2013655.","journal-title":"Blood"},{"key":"46_CR21","doi-asserted-by":"publisher","first-page":"F11","DOI":"10.1084\/jem.194.3.F11","volume":"194","author":"SL Swain","year":"2001","unstructured":"Swain SL: Interleukin 18: tipping the balance towards a T helper cell 1 response. J Exp Med 2001, 194:F11-F14.","journal-title":"J Exp Med"},{"key":"46_CR22","first-page":"4557","volume":"57","author":"MJ Micallef","year":"1997","unstructured":"Micallef MJ, Tanimoto T, Kohno K, et al.: Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res 1997, 57:4557\u20134563. A second paper in which Micallef et al. demonstrated antitumor effects of IL-18 in tumor-bearing mice.","journal-title":"Cancer Res"},{"key":"46_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s002620050345","volume":"43","author":"MJ Micallef","year":"1997","unstructured":"Micallef MJ, Yoshida K, Kawai S, et al.: In vivo antitumor effects of murine interferon-gamma-inducing factor\/ interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 1997, 43:361\u2013367. Micallef et al. demonstrated antitumor effects of IL-18 in tumorbearing mice and suggested associated immunologic specificity and memory with important involvement of both NK and CD4+ T cells in the antitumor response.","journal-title":"Cancer Immunol Immunother"},{"key":"46_CR24","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.4049\/jimmunol.160.4.1742","volume":"160","author":"T Osaki","year":"1998","unstructured":"Osaki T, Peron JM, Cai Q, et al.: IFN-gamma-inducing factor\/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol 1998, 160:1742\u20131749. This paper also suggests involvement of NK and CD4+ T cells in the described IL-18 antitumor effects.","journal-title":"J Immunol"},{"issue":"Suppl1","key":"46_CR25","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1097\/00002371-200203001-00008","volume":"25","author":"T Iwasaki","year":"2002","unstructured":"Iwasaki T, Yamashita K, Tsujimura T, et al.: Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic boneresorption in nude mice. J Immunother 2002, 25(Suppl1):S52-S60.","journal-title":"J Immunother"},{"key":"46_CR26","first-page":"1237","volume":"9","author":"K Yamashita","year":"2002","unstructured":"Yamashita K, Iwasaki T, Tsujimura T, et al.: Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow. Oncol Rep 2002, 9:1237\u20131244.","journal-title":"Oncol Rep"},{"key":"46_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1089\/107999004322917007","volume":"24","author":"T Okamoto","year":"2004","unstructured":"Okamoto T, Yamada N, Tsujimura T, et al.: Inhibition by interleukin-18 of the growth of Dunn osteosarcoma cells. J Interferon Cytokine Res 2004, 24:161\u2013167.","journal-title":"J Interferon Cytokine Res"},{"key":"46_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/00002371-200003000-00002","volume":"23","author":"T Kikuchi","year":"2000","unstructured":"Kikuchi T, Akasaki Y, Joki T, et al.: Antitumor activity of interleukin-18 on mouse glioma cells. J Immunother 2000, 23:184\u2013189.","journal-title":"J Immunother"},{"issue":"Suppl1","key":"46_CR29","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1097\/00002371-200203001-00005","volume":"25","author":"S Akamatsu","year":"2002","unstructured":"Akamatsu S, Arai N, Hanaya T, et al.: Antitumor activity of interleukin-18 against the murine T-cell leukemia\/ lymphoma EL-4 in syngeneic mice. J Immunother 2002, 25(Suppl1):S28-S34.","journal-title":"J Immunother"},{"key":"46_CR30","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.4049\/jimmunol.169.8.4467","volume":"169","author":"JM Wigginton","year":"2002","unstructured":"Wigginton JM, Lee JK, Wiltrout TA, et al.: Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol 2002, 169:4467\u20134474. This paper, along with that of Son et al. [31], suggests the importance of considering combination antitumor therapy with IL-18 and other cytokines.","journal-title":"J Immunol"},{"key":"46_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/00002371-200305000-00007","volume":"26","author":"YI Son","year":"2003","unstructured":"Son YI, Dallal RM, Lotze MT: Combined treatment with interleukin-18 and low-dose interleukin-2 induced regression of a murine sarcoma and memory response. J Immunother 2003, 26:234\u2013240.","journal-title":"J Immunother"},{"key":"46_CR32","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1096\/fasebj.13.15.2195","volume":"13","author":"R Cao","year":"1999","unstructured":"Cao R, Farnebo J, Kurimoto M, Cao Y: Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J 1999, 13:2195\u20132202.","journal-title":"FASEB J"},{"key":"46_CR33","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/sj.gt.3300908","volume":"6","author":"T Osaki","year":"1999","unstructured":"Osaki T, Hashimoto W, Gambotto A, et al.: Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther 1999, 6:808\u2013815.","journal-title":"Gene Ther"},{"key":"46_CR34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1349-7006.1997.tb00409.x","volume":"88","author":"H Fukumoto","year":"1997","unstructured":"Fukumoto H, Nishio M, Nishio K, et al.: Interferon-gammainducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo. Jpn J Cancer Res 1997, 88:501\u2013505.","journal-title":"Jpn J Cancer Res"},{"key":"46_CR35","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/sj.gt.3301291","volume":"7","author":"DW Ju","year":"2000","unstructured":"Ju DW, Yang Y, Tao Q, et al.: Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity. Gene Ther 2000, 7:1672\u20131679.","journal-title":"Gene Ther"},{"key":"46_CR36","first-page":"5853","volume":"62","author":"T Tatsumi","year":"2002","unstructured":"Tatsumi T, Gambotto A, Robbins PD, Storkus WJ: Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. Cancer Res 2002, 62:5853\u20135858.","journal-title":"Cancer Res"},{"key":"46_CR37","first-page":"6378","volume":"63","author":"T Tatsumi","year":"2003","unstructured":"Tatsumi T, Huang J, Gooding WE, et al.: Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 2003, 63:6378\u20136386.","journal-title":"Cancer Res"},{"key":"46_CR38","first-page":"491","volume":"63","author":"MT Carrascal","year":"2003","unstructured":"Carrascal MT, Mendoza L, Valcarcel M, et al.: Interleukin-18 binding protein reduces B16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 2003, 63:491\u2013497.","journal-title":"Cancer Res"},{"key":"46_CR39","first-page":"2703","volume":"60","author":"D Cho","year":"2000","unstructured":"Cho D, Song H, Kim YM, et al.: Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res 2000, 60:2703\u20132709.","journal-title":"Cancer Res"},{"key":"46_CR40","first-page":"76","volume":"23","author":"MJ Robertson","year":"2004","unstructured":"Robertson MJ, Mier J, Logan TF, et al.: Tolerability and anti-tumor activity of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in patients with solid tumors. J Clin Oncol 2004, 23:76 (Suppl; abstr 2553).","journal-title":"J Clin Oncol"},{"key":"46_CR41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1359-6349(04)80275-1","volume":"2","author":"KM Koch","year":"2004","unstructured":"Koch KM, Kwok D, McIntosh T, et al.: Pharmacokinetics and parmacodynamics of recombinant human IL-18 (rhIL-18) in patients with solid tumors. Eur J Cancer 2004 2(Suppl):82(abstract 267).","journal-title":"Eur J Cancer"},{"key":"46_CR42","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1200\/JCO.2005.00.992","volume":"23","author":"MJ Robertson","year":"2005","unstructured":"Robertson MJ, Kirkwood JM, Logan TF, et al.: Phase I study of recombinate human IL-18 (rhIL-18) administered as five daily intrvenous infusions every 28 days in patients with solid tumors. J Clin Oncol 2005, 23:2513 (Suppl; abstr 16).","journal-title":"J Clin Oncol"},{"key":"46_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/35040504","volume":"408","author":"J Parrish-Novak","year":"2000","unstructured":"Parrish-Novak J, Dillon SR, Nelson A, et al.: Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57\u201363. One of the original descriptions of IL-21.","journal-title":"Nature"},{"key":"46_CR44","doi-asserted-by":"publisher","first-page":"11439","DOI":"10.1073\/pnas.200360997","volume":"97","author":"K Ozaki","year":"2000","unstructured":"Ozaki K, Kikly K, Michalovich D, et al.: Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci U S A 2000, 97:11439\u201311444.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"46_CR45","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1189\/jlb.72.5.856","volume":"72","author":"J Parrish-Novak","year":"2002","unstructured":"Parrish-Novak J, Foster DC, Holly RD, Clegg CH: Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002, 72:856\u2013863.","journal-title":"J Leukoc Biol"},{"key":"46_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.0105-2896.2004.00201.x","volume":"202","author":"DS Mehta","year":"2004","unstructured":"Mehta DS, Wurster AL, Grusby MJ: Biology of IL-21 and the IL-21 receptor. Immunol Rev 2004, 202:84\u201395. An excellent recent review of IL-21 and its receptor.","journal-title":"Immunol Rev"},{"key":"46_CR47","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1182\/blood.V99.10.3756","volume":"99","author":"AT Brenne","year":"2002","unstructured":"Brenne AT, Baade RT, Waage A, et al.: Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 2002, 99:3756\u20133762.","journal-title":"Blood"},{"key":"46_CR48","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1615\/CritRevImmunol.v24.i4.20","volume":"24","author":"SL Nutt","year":"2004","unstructured":"Nutt SL, Brady J, Hayakawa Y, Smyth MJ: Interleukin 21: a key player in lymphocyte maturation. Crit Rev Immunol 2004, 24:239\u2013250.","journal-title":"Crit Rev Immunol"},{"key":"46_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2567.2004.01886.x","volume":"112","author":"PV Sivakumar","year":"2004","unstructured":"Sivakumar PV, Foster DC, Clegg CH: Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responses. Immunology 2004, 112:177\u2013182.","journal-title":"Immunology"},{"issue":"March","key":"46_CR50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/sj.cgt.7700552","volume":"10","author":"S Ugai","year":"2003","unstructured":"Ugai S, Shimozato O, Kawamura K, et al.: Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther 2003, 10(March):187\u2013192.","journal-title":"Cancer Gene Ther"},{"key":"46_CR51","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.4049\/jimmunol.172.4.2048","volume":"172","author":"J Brady","year":"2004","unstructured":"Brady J, Hayakawa Y, Smyth MJ, Nutt SL: IL-21 induces the functional maturation of murine NK cells. J Immunol 2004, 172:2048\u20132058.","journal-title":"J Immunol"},{"key":"46_CR52","first-page":"9016","volume":"63","author":"G Wang","year":"2003","unstructured":"Wang G, Tschoi M, Spolski R, et al.: In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003, 63:9016\u20139022.","journal-title":"Cancer Res"},{"key":"46_CR53","doi-asserted-by":"crossref","first-page":"608","DOI":"10.4049\/jimmunol.171.2.608","volume":"171","author":"HL Ma","year":"2003","unstructured":"Ma HL, Whitters MJ, Konz RF, et al.: IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFNgamma. J Immunol 2003, 171:608\u2013615.","journal-title":"J Immunol"},{"key":"46_CR54","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4049\/jimmunol.172.3.1540","volume":"172","author":"E Di Carlo","year":"2004","unstructured":"Di Carlo E, Comes A, Orengo AM, et al.: IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol 2004, 172:1540\u20131547.","journal-title":"J Immunol"},{"key":"46_CR55","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/jgm.817","volume":"8","author":"H Nakano","year":"2005","unstructured":"Nakano H, Kishida T, Asada H, et al.: Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma. J Gene Med 2005, 8:90\u201399.","journal-title":"J Gene Med"},{"key":"46_CR56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20041057","volume":"201","author":"R Zeng","year":"2005","unstructured":"Zeng R, Spolski R, Finkelstein SE, et al.: Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005, 201:139\u2013148.","journal-title":"J Exp Med"},{"key":"46_CR57","doi-asserted-by":"crossref","first-page":"900","DOI":"10.4049\/jimmunol.173.2.900","volume":"173","author":"A Moroz","year":"2004","unstructured":"Moroz A, Eppolito C, Li Q, et al.: IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 2004, 173:900\u2013909. This paper suggests substantial antitumor activity for systemic IL-21 compared with other cytokines and suggests a possible related mechanism in increased T-cell survival.","journal-title":"J Immunol"},{"key":"46_CR58","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1200\/JCO.2005.12.157","volume":"23","author":"B Curti","year":"2005","unstructured":"Curti B, Redman BG, Thompson JA, Sievers EL: Preliminary tolerability and anti-tumor activity of intravenous recombinate human interleukin-21 (IL-2) in patients with metastatic melanoma and metastatic renal cell carcinoma. J Clin Oncol 2005, 23:2502 (Suppl; abstr).","journal-title":"J Clin Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-006-0046-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-006-0046-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-006-0046-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-006-0046-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T01:09:14Z","timestamp":1683853754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-006-0046-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["46"],"URL":"https:\/\/doi.org\/10.1007\/s11912-006-0046-0","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}